Limits...
Economic analysis of opportunities to accelerate Alzheimer's disease research and development.

Scott TJ, O'Connor AC, Link AN, Beaulieu TJ - Ann. N. Y. Acad. Sci. (2014)

Bottom Line: The development of disease-modifying treatments for Alzheimer's disease (AD) faces a number of barriers.Estimates based on interviews with experts on AD research and development suggest that the cost of one new drug is now $5.7 billion (95% confidence interval (CI) $3.7-9.5 billion) and could be reduced to $2.0 billion (95% CI $1.5-2.9 billion).The associated acceleration in the arrival of disease-modifying treatments could reduce the number of case years of dementia by 7.0 million (95% CI 4.4-9.4 million) in the United States from 2025 through 2040.

View Article: PubMed Central - PubMed

Affiliation: RTI International, Research Triangle Park, North Carolina.

Show MeSH

Related in: MedlinePlus

Expected capitalized cost to develop a disease-modifying drug for AD
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4285871&req=5

fig01: Expected capitalized cost to develop a disease-modifying drug for AD

Mentions: The expected capitalized cost of developing a disease-modifying drug for AD is estimated to be $5,693 million (95% CI, $3,691–9,541 million) in the current environment with the existing infrastructure and $2,027 million (95% CI, $1,453–2,935 million) in an environment with the improved infrastructure (Fig. 1).k Thus, an improved technical and research infrastructure supporting AD research and drug development is expected to reduce the cost of the first disease-modifying AD therapeutic by $3,667 million (95% CI, $1,340–5,994 million).l


Economic analysis of opportunities to accelerate Alzheimer's disease research and development.

Scott TJ, O'Connor AC, Link AN, Beaulieu TJ - Ann. N. Y. Acad. Sci. (2014)

Expected capitalized cost to develop a disease-modifying drug for AD
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4285871&req=5

fig01: Expected capitalized cost to develop a disease-modifying drug for AD
Mentions: The expected capitalized cost of developing a disease-modifying drug for AD is estimated to be $5,693 million (95% CI, $3,691–9,541 million) in the current environment with the existing infrastructure and $2,027 million (95% CI, $1,453–2,935 million) in an environment with the improved infrastructure (Fig. 1).k Thus, an improved technical and research infrastructure supporting AD research and drug development is expected to reduce the cost of the first disease-modifying AD therapeutic by $3,667 million (95% CI, $1,340–5,994 million).l

Bottom Line: The development of disease-modifying treatments for Alzheimer's disease (AD) faces a number of barriers.Estimates based on interviews with experts on AD research and development suggest that the cost of one new drug is now $5.7 billion (95% confidence interval (CI) $3.7-9.5 billion) and could be reduced to $2.0 billion (95% CI $1.5-2.9 billion).The associated acceleration in the arrival of disease-modifying treatments could reduce the number of case years of dementia by 7.0 million (95% CI 4.4-9.4 million) in the United States from 2025 through 2040.

View Article: PubMed Central - PubMed

Affiliation: RTI International, Research Triangle Park, North Carolina.

Show MeSH
Related in: MedlinePlus